Introduction {#S0001}
============

Acute pain represents a critical and frequent issue in the emergency setting and requires an effective, safe, and manageable therapeutic approach. In elderly patients, treatment of acute pain presents additional difficulties due to cognitive and physical status, and concurrent conditions and medications.[@CIT0001] Commonly used drugs may cause potential adverse events (eg, nephrological and/or gastrointestinal events with nonsteroidal anti-inflammatory drugs \[NSAIDs\])[@CIT0002] or may be inadequate for severe pain (eg, paracetamol).[@CIT0003] Opioids for severe pain in the elderly may cause cognitive impairment, delirium, respiratory depression, sedation, and other potentially severe side effects,[@CIT0004] limiting their routine use.

Low-dose-inhaled methoxyflurane (Penthrox^®^, 3 mL dose, Medical Developments International, Scoresby, Australia) is a non-opioid, volatile fluorinated analgesic, self-administered through an easy-to-use device handled by the patient.[@CIT0005]--[@CIT0007] Methoxyflurane is currently available in Europe for the emergency relief of moderate-to-severe pain in conscious adults with trauma and associated pain,[@CIT0006] based on clinical evidence from a randomized, placebo-controlled trial (STOP!) conducted in UK emergency departments (EDs).[@CIT0008] More recently, the MEDITA (Methoxyflurane in Emergency Department in Italy) trial[@CIT0009]--[@CIT0011] demonstrated superiority of methoxyflurane versus standard analgesic treatment (SAT), consisting of intravenous (IV) paracetamol or ketoprofen for moderate pain and IV morphine for severe pain, in terms of pain reduction up to 30 min after randomization, onset of pain relief, and satisfaction of healthcare professionals and patients. Subgroup analyses according to baseline pain (moderate, severe) showed that methoxyflurane was more effective than SAT in both cases.

Currently, the evidence in the literature and the therapeutic indication refer to the whole adult population aged over 18 years, and specific efficacy and safety data in the elderly population are missing. The objective of this post-hoc analysis of the MEDITA study is to evaluate the efficacy, safety, and user-satisfaction of inhaled methoxyflurane vs SAT in patients with acute trauma pain aged 65 years or older.

Patients and Methods {#S0002}
====================

Study Design {#S0002-S2001}
------------

MEDITA was designed as a Phase IIIb, randomized, active-controlled, parallel-group, open-label study. Patients were enrolled from 08 February 2018 to 22 February 2019 at 16 prehospital units and EDs in Italy. The study was registered with EudraCT number 2017-001565-25, and Clinicaltrials.gov identifier NCT03585374. Previous published papers reported methods and rationale of the protocol,[@CIT0009] results for the full study population,[@CIT0010] and results for the population with severe pain.[@CIT0011]

Briefly, patients who went to the hospital emergency department on their own or were rescued in extra-hospital setting, and who had moderate (NRS 4--6) to severe (NRS 7--10) pain due to trauma in a single limb, were randomized (1:1) to inhaled methoxyflurane (experimental arm) or SAT (control arm). Treatment and evaluations were performed on the day of randomization, and 14 days after discharge, a phone call was made to gather additional information.

The study was performed following current and local ethical standards, Good Clinical Practices, 1964 Helsinki Declaration and its later amendments. Before the start of the study, Italian Medicines Agency (AIFA) and local Ethics Committees reviewed and approved the protocol. Each patient had to express their informed consent prior to enrollment. Due to clinical conditions, if the patient was unable to provide written consent, a verbal consent was obtained with the presence of an impartial witness, and the patient's signature was obtained as soon as conditions permitted. In addition to the monitoring carried out by the Contract Research Organization, an external GCP audit and a GCP inspection by AIFA have been carried out.

Participants {#S0002-S2002}
------------

The original study included adult (≥18 years old) patients with moderate-to-severe pain (numerical rating score ≥4) secondary to a trauma (fracture, dislocation, crushing, contusion) to a single limb. In the present subgroup analysis, only patients aged ≥65 years were included. This cut off was selected as it is commonly accepted to define an elderly population. The complete list of inclusion and exclusion criteria was previously reported by Fabbri et al.[@CIT0009] Briefly, patients were medically stable, conscious, and collaborating in order to express informed consent and follow the study procedures. Patients must not have taken any medicines for chronic pain or any other analgesic in the previous 5 h (8 h for diclofenac). Patients were excluded also in case of contraindications to methoxyflurane administration as per the Summary of Product Characteristics (SPC)[@CIT0012] or to any of the SAT.

Randomization and Interventions {#S0002-S2003}
-------------------------------

Non-stratified blocks of four were used for randomization, and the procedure started with the verification of the eligibility criteria. Treatment allocation was concealed to investigators thanks to a centralized Interactive Web Response System integrated with the electronic case report form (eCRF). The study was open-label because of feasibility reasons: the sponsor and the investigator believed that adopting a double-blind, double-dummy design (to mask the different routes of administration) in the emergency context was too complex.

After randomization, drug administration took place in the shortest possible time. Patients in the experimental arm received only one 3 mL methoxyflurane inhaler, prepared by trained study staff in agreement with SPC recommendations. Administration was supervised by the investigator and started intermittently. Subsequently, patients could increase the frequency of inhalation or cover the diluting hole to obtain a greater analgesic effect, according to a patient-controlled analgesia. The patient's exhalation takes place through the same mouthpiece of the inhalation, in fact the outgoing air is filtered by activated carbon, preventing environmental release of methoxyflurane and potential occupational exposure. A single 3 mL inhaler provides approximately 25 to 60 min analgesia based on the intensity and frequency of inhalation of the individual patient.[@CIT0012] The sponsor provided methoxyflurane in packs containing inhaler and a 3 mL methoxyflurane vial.

Patients randomized to the control arm received treatment according to the individual baseline pain intensity. Study procedures assigned patients with moderate pain (NRS 4--6) to IV paracetamol (1 g) or ketoprofen (100 mg), based on the practice of the individual center and any contraindications for the patient. Patients with severe pain (NRS ≥7) were assigned to IV morphine (0.10 mg/kg). Venous access, in agreement with local practice, was taken before randomization; then, dilution and infusion of the drug occurred within 10 min. SATs were commercially available products supplied locally by study centers.

Rescue medications were up to the investigator's choice and were allowed at any time after randomization in case pain was not adequately controlled by study treatment.

Study Assessments {#S0002-S2004}
-----------------

The primary objective of the full study was to demonstrate that the efficacy of inhaled methoxyflurane was non-inferior to the SAT up to 10 min, measured through the overall change in the VAS scale from baseline to 3, 5, and 10 min. To collect additional efficacy data, pain intensity was measured up to 30 min (15, 20, 25, and 30 min), or until administration of rescue medication. Patients had to independently mark the VAS scale; however, if clinical conditions (eg, trauma to the hand) did not allow this operation, a properly trained operator could offer support. The NRS scale was used only for enrollment. For the efficacy measures, the VAS scale was chosen because it is continuous and able to increase the sensitivity and power of the study. Additional efficacy parameters included time from randomization to the onset of analgesic effect reported by the patient and administration of any rescue medication. The satisfaction parameters included the judgment of patients on efficacy and investigators on practicality. In both cases, the measurement was done with a 5-point Likert scale (poor, fair, good, very good, excellent) at 30 min after randomization.

Safety parameters were incidence of adverse events (AEs), serious AEs not related to the trauma presentation, and vital signs (systolic and diastolic blood pressure \[SBP and DBP\], heart rate, and respiratory rate). Safety evaluations were performed at baseline and 10 and 30 min after randomization.

For all evaluations, randomization was selected as baseline. Given that the next sequential operations were the preparation or dilution of the medicine, and therefore the start of administration, also the practicality and speed of preparation, in addition to the intrinsic effect of the drug, had a role on efficacy.

Statistical Analysis {#S0002-S2005}
--------------------

To compare the VAS pain intensity variation from baseline between study treatments, a linear mixed-effect model for repeated measures adjusted for VAS baseline score, and the interaction between time point and treatment was used. The primary analysis was the overall test for treatment effect at 3, 5, and 10 min. For each analysis, the treatment difference (methoxyflurane-control) was presented with 95% confidence interval (CI): if the upper limit was \<1, non-inferiority of methoxyflurane vs control was concluded; if the upper limit was \<0, superiority was concluded.

The mean change from baseline in VAS pain intensity at following time points (15, 20, 25, 30 min) was estimated for each group with 95% CI and the *t*-test for equality of means was used to compare treatment effects. Time to onset of pain relief was presented with Kaplan--Meier curves, with "survival time" representing the event "onset of pain relief". Frequency of rescue medication administration between groups was tested using Fisher's exact test. User satisfaction (efficacy for patients and practicality for investigators) between groups was compared using the Mann--Whitney *U*-test. For efficacy variables, the intention-to-treat (ITT) population approach was adopted, and no imputation of missing data was performed.

Only analyses of the ITT population were performed since it was a post-hoc, exploratory study on a small population, and since in the total population[@CIT0010] the ITT and PP results were similar. Furthermore, only 2 cases would have been excluded in the PP analysis.

AEs were classified using the Medical Dictionary for Regulatory Activities version 22.0 and presented for the safety population (based on administered treatment). Statistics were performed with IBM SPSS Statistics version 23.0.

Sample Size {#S0002-S2006}
-----------

The sample size calculation for the full study is reported in a previous paper[@CIT0009] and planned to randomize 136 patients per treatment arm. In this report, data from 69 elderly patients are presented, and as a post-hoc analysis, a formal sample size was not calculated. Thus, the present analysis was conducted in an exploratory manner only. Furthermore, the proportion of elderly patients at the beginning of the study was not predictable, thus.

Results {#S0003}
=======

Study Patients {#S0003-S2001}
--------------

Among the 272 patients randomized in the full study,[@CIT0010] 69 (25%) were ≥65 years of age and included in the present post hoc analysis. Baseline characteristics of elderly patients subgroup are shown in [Table 1](#T0001){ref-type="table"}; 35 (50.7%, mean age 75) of those received methoxyflurane and 34 (49.3%, mean age 76.4) received SAT. In both groups, most patients were female and Caucasian, a similar proportion of severe and moderate pain level was present. Contusion and fracture were the most common suspected injury types at inclusion. In the control group, all patients with severe pain (15; 44.1%) were treated with IV morphine, and patients with moderate pain were treated with IV paracetamol (16; 47.1%) or IV ketoprofen (3; 8.8%). At baseline, mean VAS pain intensity was 73 (±18\[SD\]) in the overall elderly population, 71 (±20\[SD\]) in the methoxyflurane group, and 76 (±16\[SD\]) in the control group.Table 1Baseline CharacteristicsCharacteristicsMethoxyflurane (N=35)Standard Analgesic Treatment (SAT) (N=34)Age (years)Mean (SD)75 (6.8)76,4 (7.7)Range65--9165--95Gender \[n (%)\]Male5 (14)6 (18)Female30 (86)28 (82)Weight (kg)Mean (SD)69 (10.2)69 (10.3)Range50--9450--85Race \[n (%)\]Caucasian34 (97)34 (100)Asian1 (3.0)0Black00Other00Baseline pain group \[n (%)\]Moderate \[NRS 4--6\]18 (51)19 (56)Severe \[NRS ≥7\]17 (49)15 (44)Suspected injury type at inclusion \[n (%)\]Contusion15 (43)15 (44)Fracture15 (43)13 (38)Dislocation5 (14)5 (15)Crushing01 (3)

Efficacy Results {#S0003-S2002}
----------------

Pain reduction according to VAS over time was very similar in both study groups ([Figure 1](#F0001){ref-type="fig"}). Median time to onset of pain relief was shorter for methoxyflurane (9 min; 95% CI: 7.8, 10.2 min) than SAT (15 min; 95% CI: 10.2, 19.8 min), with the faster time to pain relief for methoxyflurane evident in Kaplan--Meier curves up to \~25 min ([Figure 2](#F0002){ref-type="fig"}). At 10 min about 80% of patients reported pain relief the methoxyflurane group vs about 40% of patients in the SAT group. There was no difference between the treatment groups in the proportion of patients who received rescue analgesic medication (methoxyflurane: 2 patients \[5.7%\]; SAT: 1 patient \[2.9%\]; p=1.000).Figure 1Pain reduction. Mean ± standard error. n=69. SAT: standard analgesic treatment (moderate pain: IV paracetamol or IV ketoprofen; severe pain: IV morphine).Figure 2Time to pain relief.

In terms of treatment satisfaction, patients rated treatment efficacy as "Excellent" or "Very good" 5.7 times more frequently than SAT (34.3% vs 6%), and healthcare professionals rated practicality as "Excellent" or "Very good" 3.4 times more frequently than SAT (60.0% vs 17.7%). Overall, the distribution of patients' efficacy ratings and physicians' practicality was significantly different between treatments (p=0.040 and p=0.003, respectively, [Figure 3](#F0003){ref-type="fig"}).Figure 3Overall treatment efficacy evaluated by patients and practicality by HCPs. Cumulative proportions of 5-point Likert qualitative scale ("Poor", "Fair", "Good", "Very Good", or "Excellent") at 30 min after randomization. SAT: standard analgesic treatment (moderate pain: IV paracetamol or IV ketoprofen; severe pain: IV morphine). P-value = 0.04 (Mann--Whitney *U*-test).

Safety Results {#S0003-S2003}
--------------

A total of 13 adverse events (methoxyflurane: 6 events; SAT: 7 events) were recorded during the study (all non-serious; [Table 2](#T0002){ref-type="table"}). Six events were related or possibly related to study treatment (methoxyflurane, 4 events: 1 vertigo, 2 nausea, 1 somnolence; paracetamol, 2 events: 1 presyncope, 1 hypotension). Three patients discontinued methoxyflurane treatment due to AEs.Table 2Adverse EventsAdverse EventsParacetamol (N=16)Paracetamol -- %Methoxyflurane (N=35) -- NMethoxyflurane -- %Total (N=69) -- NTotal -- %Vertigo00.0%12.9%11.4%Constipation16.3%00.0%11.4%Nausea16.3%25.7%34.3%Vomiting16.3%00.0%11.4%Bronchitis00.0%12.9%11.4%Presyncope212.5%12.9%34.3%Somnolence00.0%12.9%11.4%Hyperhidrosis16.3%00.0%11.4%Hypotension16.3%00.0%11.4%

There were no clinically significant changes in vital signs parameters (blood pressure, heart rate, respiratory rate) in both groups, complete data are reported in [[Tables S1--S9](http://www.dovepress.com/get_supplementary_file.php?f=255532.docx)]{.ul}.

Discussion {#S0004}
==========

This subgroup analysis of the randomized, active-controlled trial MEDITA showed similar efficacy and safety of inhaled methoxyflurane compared to SAT in terms of pain intensity up to 30 min after randomization. On the other hand, inhaled methoxyflurane showed two relevant advantages over SAT: faster onset of analgesia, and higher user satisfaction. To the best of our knowledge, this is the first study which specifically addresses the use of inhaled methoxyflurane in the elderly population. Our results support the use of the inhaled methoxyflurane in the elderly population as a new therapeutic option, able to offer a faster reduction of pain and a better user experience. Given the urgency and complexity of pain management in the emergency situations, and the peculiarity of the study population, these results are clinically relevant.

As recommended by current SmPC,[@CIT0012] caution should be paid in elderly patients because of potential effects on blood pressure and heart rate were reported with high dose methoxyflurane used in anesthesia. As the risk may potentially be increased for older people with hypotension and bradycardia, caution should be paid in the elderly due to possible reduction in blood pressure. According to the exclusion criteria of the present study, patients had normal signs at inclusion. Overall, a low number of adverse events, all non-serious and transient, occurred in the study, and vital signs did not change significantly. Since analgesia is controlled by the patient, it is possible to control and limit the occurrence of adverse events related to drug exposure, modulating drug intake according to subjective need and tolerability. Furthermore, since the overall dose is low (up to 6 mL with 2 consecutive administrations allowed in clinical practice), the risk of overdose is reduced. Any adverse event can be controlled through the temporary or permanent suspension of treatment. Therefore, our results support a safe use of inhaled methoxyflurane in the elderly population. For these patients, an additional therapeutic option may be useful, since comorbidities and potential adverse or contraindication may limit the use of other common agents, eg, NSAID, and opioids. In addition, intravenous drugs may be non-administrable due to the low venous patrimony in some patients.

The higher user's satisfaction is a particularly relevant result in this setting. The elderly population often presents complex and fragile conditions and is generally more suspicious of new technologies than young people. Inhaled methoxyflurane offers less invasive treatment than IV therapies, and requires active patient participation in controlling analgesia. In an emergency context, both in the hospital and especially in an out-of-hospital setting, a better perception of the therapy may potentially reduce tension/stress and facilitate the treatment process.

Treatment of acute pain is important to stop the stress reaction. The stress reaction triggered by pain causes physio-pathological reactions such as increased arterial pressure, tachycardia, tachypnea, and other endocrine-metabolic phenomena,[@CIT0013] which can precipitate the clinical pictures in patients with comorbidities and reduced functional reserves such as the elderly. Follow-up studies on long-term post-traumatic pain have shown that pain at the time of trauma is considered the main independent factor of chronic and long-term pain.[@CIT0014] In this perspective, it is important to relieve acute trauma pain quickly and effectively.

The limitations of the present study include the exploratory, post-hoc nature of the analysis, and the absence of sample size calculation to detect differences of efficacy and safety between the two groups. For this reason, the results, although encouraging and in line with the previous evidence in the literature, must be interpreted with caution and cannot be considered definitive. Additional limitations of the study, as previously discussed,[@CIT0010] include the open-label design which represents an intrinsic bias, but it was necessary to guarantee the feasibility of the study considering the emergency setting. Given these limitations, further adequately designed head-to-head studies are needed to detect treatment differences in the efficacy of inhaled methoxyflurane vs SAT in elderly patients with trauma pain.

In conclusion, inhaled methoxyflurane showed similar pain relief and safety compared to IV standard in elderly patients with moderate to severe trauma pain, providing advantages in terms of onset of effect and user's satisfaction. Although the study presents a number of limitations due to the post hoc analysis of a randomized open-label study, it provides the first specific evidence of the use of inhaled methoxyflurane in the elderly population.
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